Blood management

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 5, 2007, Pages 695-701

  Goodnough, Lawrence T ^a   Shander, Aryeh ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; DESMOPRESSIN; ERYTHROPOIETIN; IRON; IRON DEXTRAN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

BLOOD AUTOTRANSFUSION; BLOOD CLOTTING; BLOOD SAMPLING; BLOOD STORAGE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; ELECTIVE SURGERY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; HEMODILUTION; HEMOGLOBIN BLOOD LEVEL; HEMOPHILIA A; HEMOPHILIA B; HOSPITAL PHYSICIAN; HUMAN; INFORMED CONSENT; INTRAOPERATIVE PERIOD; IRON DEFICIENCY ANEMIA; PATIENT POSITIONING; PHLEBOTOMY; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PREOPERATIVE TREATMENT; REVIEW; ROOM TEMPERATURE; SURGICAL TECHNIQUE; TREATMENT PLANNING;

BLOOD COMPONENT TRANSFUSION; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; ERYTHROPOIETIN; HEMOSTATICS; HUMANS; INTRAOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE;

EID: 34248219461     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Society for Advancement of Blood Management (SABM). Available at: www.sabm.org. Accessed July 31, 2006.
2. American Association of Blood Banks, America's Blood Centers, and American Red Cross. Circular of Information for the Use of Human Blood and Blood Components. Bethesda, Md: American Association of Blood Banks; 2000.
3. Practice guidelines for blood component therapy. American Society of Anesthesia. Anesthesiology. 1996;84:732-747.
4. Goodnough LT, Johnston MFM, Toy PT. The variability of transfusion practice in coronary artery bypass surgery. JAMA. 1991;265:86-90.
5. Stover EP, Siegl LC, Parks R, et al. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24 institution study. Anesthesiology. 1998;88:327-333.
6. Ozier Y, Pessione F, Samain E, Courtois F. Institutional variability in transfusion practice for liver transplantation. Anesth Analg. 2003;97:671-679.
7. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking towards the future. Lancet. 2003;361s:161-169.
8. Spahn DR, Casuutt M. Eliminating blood transfusions: new aspects and perspectives. Anesthesiology. 2000;93:242-255.
9. Hebert PC, Wells C, Blajchman MA, for the Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med. 1999;340:409-417.
10. Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who receive blood transfusion. Transfusion. 2002;42:812-818.
11. Goodnough LT, Shander A, Spence R. Bloodless medicine. Transfusion. 2003;43:668-676.
12. Hutchinson AB, Fergusson D, Graham ID, Laupacis A, Herrin J, Hillyer CD. Utilization of technologies to reduce allogeneic blood transfusion in the United States. Transf Med. 2001;11:79-85.
13. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med. 1997;336:933-938.
14. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross donor population. Transfusion. 2002;42:475-479.
15. Centers for Disease Control. Investigations of West Nile virus infections in recipients of blood transfusions. Available at: MMWR.www.cdc.gov/mm... iew/ mmwrrhtml/dispatch-westnile.htm. Accessed October 31, 2002.
16. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine, part I: blood transfusion. N Engl J Med. 1999;340:439-447.
17. Van der Linden P, De Hert S, Daper A, et al. A standardized multidisciplinary approach reduces the use of allogeneic blood products in patients undergoing cardiac surgery. Can J Anaesth. 2001;48:894-901.
18. Goodnough LT, Shander A, Spivak JL, et al. Detection, evaluation, and management of anemia in the elective surgical patient. Anesth Analg. 2005;101: 1858-1861.
19. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements. N Engl J Med. 1986; 314:1233-1235.
20. Brecher ME, Goodnough LT. The rise and fall of preoperative autologous blood donation. Transfusion. 2001;41:1459-1462.
21. Goodnough LT, Brecher ME, Kanter MH, Aubuchon JP. Transfusion medicine, part II: blood conservation. N Engl J Med. 1999;340:525-533.
22. Forgie M, Wells P, Laupacis A, Fergusson D. Preoperative autologous donation decreases allogeneic transfusion but increases exposure to all red cell transfusion: results of a meta analysis. International Study of Perioperative Transfusion (ISPOT) Investigators. Arch Intern Med. 1998;158:610-616.
23. Mackey J, Lipton KS. Association Bulletin 95-4, AABB Position on Testing of Autologous Units. Bethesda, Md: American Association of Blood Banks; 1995.
24. Kurtz SB, Frost DB. A comparison of two surgical techniques for performing mastectomy. Eur J Surg Oncol. 1995;21(2):143-145.
25. Braswell C, Campos J, Spence RK. Reducing operative blood loss during hepatic surgery: from the middle ages to the space age. Curr Surg. 2001;58:472-477.
26. Wang GJ, Hungerford DS, Savory CG, et al. Use of fibrin sealant to reduce bloody drainage and hemoglobin loss after total knee arthroplasty: a brief note on a randomized prospective trial. J Bone Joint Surg. 2001;83A:1503-1505.
27. Schneeberger AG, Schulz RF, Ganz R. Blood loss in total hip arthroplasty. Lateral position combined with preservation of the capsule versus supine position combined with capsulectomy. Arch Orthop Trauma Surg. 1998;117(1-2):47-49.
28. Schmied H, Schiferer A, Sessler DI, Meznik C. The effects of red-call scavenging, hemodilution, and active warming on allogenic blood requirements in patients undergoing hip or knee arthroplasty. Anesth Analg. 1998;86:387-391.
29. Goodnough LT, Monk TG, Brecher ME. Acute normovolemic hemodilution should replace the preoperative donation of autologous blood as a method of autologous-blood procurement. Transfusion. 1998;38:473-476.
30. Monk TG, Goodnough LT, Birkmeyer JD, et al. Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy. Transfusion. 1995;35:559-565.
31. Waters JH, Biscotti C, Potter PS, Phillipson E. Amniotic fluid removal during cell salvage in the cesarean section patient. Anesthesiology. 2000;92:1531-1536.
32. Goodnough LT, Monk TG, Sicard G, et al. Intraoperative salvage in patients undergoing elective abdominal aneurism repair: an analysis of costs and benefits. J Vasc Surg. 1996;24:213.
33. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in patients with cardiovascular disease? Crit Care Med. 2001;29:227-234.
34. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood. 2000;96:823-833.
35. Goodnough LT, Brittenham G. Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs. J Lab Clin Med. 1990;115:28-35.
36. Goodnough LT, Price TH, Rudnick S, Soegiarso RW. Preoperative red blood cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion. 1992;32:441-445.
37. Goodnough LT, Verbrugge D, Marcus RE, Goldberg V. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell expansion. J Am Coll Surg. 1994;179:171-176.
38. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med. 1995;126:57-64.
39. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang. 1998;75:128-133.
40. Goodnough LT, Price TH, Parvin CA, et al. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haematol. 1994;87:695-699.
41. Coleman PH, Stevens AR, Dodge HT, Finch CA. Rate of blood regeneration after blood loss. Arch Intern Med. 1953;92:341-348.
42. Crosby WH. Treatment of hemochromatosis by energetic phlebotomy: one patient's response to getting 55 liters of blood in 11 months. Br J Haematol. 1958; 4:82-88.
43. Goodnough LT, Merkel K. The use of parenteral iron and recombinant human erythropoietin therapy to stimulate erythropoiesis in patients undergoing repair of hip fracture. Int J Hematol. 1996;1:163-166.
44. Finch CA. Erythropoiesis, erythropoietin, and iron. Blood. 1982;60:1241-1246.
45. Muirhead M, Bargman J, Burgess E, et al. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis. 1995;26(2 suppl 1):S1-S24.
46. Kaisi M, Ngwalle EWK, Runyoro DE, Rogers J. Evaluation and tolerance of response to iron dextran (Imferon) administered by total dose infusion to pregnant women with iron deficiency anemia. Int J Gynecol Obstet. 1988;26:235-243.
47. Mays T, Mays T. Intravenous iron dextran therapy in the treatment of anemia occurring in surgical, gynecologic, and obstetric patients. Surg Gynecol Obstet. 1976;143:381-384.
48. Hillman RS, Henderson PA. Control of marrow production by the level of iron supply. J Clin Invest. 1969;48:454-460.
49. Henderson PA, Hillman RS. Characteristics of iron dextran utilization in man. Blood. 1969;34:357-375.
50. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 2003;17(suppl 1):S1-S5.
51. De Gasperi A. Intraoperative use of recombinant activated factor VII (r-FVIIa). Minerva Anestesiol. 2006;72:489-494.
52. Chiara O, Cimbanassi S, Brioschi PR, Bucci L, Terzi V, Vesconi S. Treatment of critical bleeding in trauma patients. Minerva Anestesiol. 2006;72:383-387.
53. Gowers CJD, Parr MJA. Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy. Anaesth Intensive Care. 2005;33:196-200.
54. Goodnough LT. Experiences with recombinant human factor VIIa in patients with thrombocytopenia. Semin Hematol. 2004;41(1 suppl 1):25-29.
55. Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg. 2003;98: 737-740.
56. Heilmann L, Wild C, Hojnacki B, Pollow K. Successful treatment of life-threatening bleeding after cesarean section with recombinant activated factor VII. Clin Appl Thromb Hemost. 2006;12:227-229.
57. Karadimov D, Krassimir B, Nachkov Y, Platikanov V. Use of activated recombinant factor VII (NovoSeven) during neurosurgery. J Neurosurg Anesthesiol. 2003;15:330-332.
58. Karkouti K, Beattie WS, Wijeysundera DN, et al. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case control analysis. Transfusion. 2005;45:26-34.
59. Romagnoli S, Bevilacqua S, Gelsomino S, et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg. 2006;102: 1320-1326.
60. Friederich PW, Henny CP, Messelink EJ, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet. 2003; 361:201-205.
61. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel, randomized placebo-controlled, double-blind clinical trials. J Trauma. 2005;59: 8-18.
62. Lodge JP, Jonas S, Oussoultzoglou E, et al. Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology. 2005;102:269-275.
63. Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double blind, randomized, placebo-controlled trial. Br J Anaesth. 2005;94:586-591.
64. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004;44:1325-1331.
65. O'Connell KA, Wood SS, Wise RP, Lozier JN, Braun NM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-298.
66. Levy JH, Fingerhut A, Brott T, et al. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis or severe traumatic injury: review of safety profile. Transfusion. 2006;46:919-933.
67. Levi M, Peteres M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review (review). Crit Care Med. 2005;33:883-890.
68. Shander A, Goodnough LT, Ratko T, et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven®) therapy. Pharm Ther. 2005;30:644-658.
69. Levy JH. Hemostatic agents. Transfusion. 2004;44(12 suppl):58S-62S.
70. Ozier Y, Schlumberger S. Pharmacological approaches to reducing blood loss and transfusions in the surgical patient. Can J Anaesth. 2006;53(6 suppl): S21-S29.
71. Royston D. Aprotinin versus lysine analogues: the debate continues. Ann Thorac Surg. 1998;65(4 suppl):S9-S19; discussion S27-S28.
72. Murkin JM, Haig GM, Beer KJ, et al. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am. 2000;82:675-684.
73. Levy JH. Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation. Am J Health Syst Pharm. 2005;62(18 suppl 4):S15-S19.
74. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2001; (1):CD001886.
75. Carless PA, Moxey AJ, Stokes BJ, Henry DA. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials. BMC Cardiovasc Disord. 2005;5:19.
76. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet. 1999;354:1940-1947.
77. Engles L. Review and application of serine protease inhibition in coronary artery bypass graft surgery. Am J Health Syst Pharm. 2005;62(18 suppl 4):S9-S14.
78. Trasylol® (aprotinin injection) [package insert]. West Haven, Conn: Bayer Pharmaceuticals Corp; December 2003.
79. FDA Public Health Advisory - Aprotinin Injection (Marketed as Trasylol). Available at: http://www.fda.gov/cder/drug/advisory/aprotinin.htm. Accessed July 17, 2006.
80. Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353-365.
81. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion. 2006;46:327-338.
82. Kikura M, Levy JH, Tanaka KA, Ramsay JG. A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg. 2006;202:216-222.
83. Camarasa MA, Olle G, Serra-Prat M, et al. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial. Br J Anaesth. 2006;96:576-582.
84. Amicar® (aminocaproic acid), injection, oral solution, and tablets [package insert]. Newport, Ky: Xanodyne Pharmaceuticals, Inc; April 2005.
85. Mabdy AM, Webster NR. Perioperative systemic haemostatic agents. Br J Anaesth. 2004;93:842-858.
86. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: a double-blind randomized trial. N Engl J Med. 1986;314:1402-1406.
87. Sagripanti A, Sarteschi LM, Camici M, et al. Nontransfusional haemostatic agents in the management of bleeding disorders. Intern Med. 2001;9:10-18.
88. Moskowitz DM, Klein JJ, Shander A, et al. Predictors of transfusion requirements for cardiac surgical procedures at a blood conservation center. Ann Thor Surg. 2004;77:626-634.